{"id":793096,"date":"2024-12-06T09:18:11","date_gmt":"2024-12-06T14:18:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/"},"modified":"2024-12-06T09:18:11","modified_gmt":"2024-12-06T14:18:11","slug":"aim-immunotech-participates-in-virtual-investor-kol-connect-segment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","title":{"rendered":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment"},"content":{"rendered":"
\n

\n Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available <\/em>
\n
\n
\n here<\/u>
\n <\/em>
\n <\/a>\n <\/p>\n

OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc.<\/strong><\/a> (NYSE American: AIM)\u00a0<\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp<\/a>, AIM\u2019s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years.<\/p>\n

As part of the segment, Dr. Lapp discussed results<\/a> from AIM\u2019s Phase 2 study evaluating the efficacy and safety of Ampligen\u00ae as a potential therapeutic for people with the Post-COVID condition of fatigue (\u201cAMP-518\u201d; NCT05592418<\/a>).<\/p>\n

The Virtual Investor KOL Connect Segment can be accessed here<\/a>.<\/p>\n

\n About AIM ImmunoTech Inc.<\/strong>\n <\/p>\n

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen\u00ae<\/sup>\u00a0(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n

For more information, please visit\u00a0aimimmuno.com<\/a>\u00a0and connect with the Company on\u00a0X<\/a>,\u00a0LinkedIn<\/a>, and\u00a0Facebook<\/a>.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

\n
Investor Contact:\r\n\r\nJTC Team, LLC\r\nJenene Thomas\r\n908.824.0775\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"
Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM\u2019s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years. As part of the segment, Dr. Lapp discussed results from AIM\u2019s Phase 2 study evaluating the efficacy and safety of Ampligen\u00ae as a potential therapeutic for people with the Post-COVID condition of fatigue (\u201cAMP-518\u201d; … <\/p>\n
Continue reading “AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793096","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM\u2019s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years. As part of the segment, Dr. Lapp discussed results from AIM\u2019s Phase 2 study evaluating the efficacy and safety of Ampligen\u00ae as a potential therapeutic for people with the Post-COVID condition of fatigue (\u201cAMP-518\u201d; … Continue reading "AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-06T14:18:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment\",\"datePublished\":\"2024-12-06T14:18:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/\"},\"wordCount\":230,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/\",\"name\":\"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=\",\"datePublished\":\"2024-12-06T14:18:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk","og_description":"Segment featuring Dr. Charles Lapp, ME\/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM\u2019s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years. As part of the segment, Dr. Lapp discussed results from AIM\u2019s Phase 2 study evaluating the efficacy and safety of Ampligen\u00ae as a potential therapeutic for people with the Post-COVID condition of fatigue (\u201cAMP-518\u201d; … Continue reading \"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-06T14:18:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment","datePublished":"2024-12-06T14:18:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/"},"wordCount":230,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/","name":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=","datePublished":"2024-12-06T14:18:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMxNTE0MSM2NjI1NjU5IzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-participates-in-virtual-investor-kol-connect-segment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Participates in Virtual Investor KOL Connect Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793096"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793096\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}